FAQ

Anti-HER3 Monoclonal Antibody LJM716

Known as: LJM716 
A human monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. Anti… (More)

Topic mentions per year

Topic mentions per year

2013-2016
012320132016

Related topics

Related topics

1 relation
antigen binding

Related mentions per year

Related mentions per year

1957-2018
1960198020002020
Anti-HER3 Monoclonal Antibody LJM716
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Background Plasticity of the ERBB receptor network has been suggested to cause acquired resistance to anti-human epidermal growth… (More)
Is this relevant?
2017
2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing…
Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
  • table 4
Is this relevant?
2016
2016
LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
Human epidermal growth factor receptor 3 (HER3) has been identified as an important component of many receptor tyrosine kinase… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Review
2016
Review
2016
HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy.
UNLABELLED Emerging evidence suggests that human epidermal growth factor receptor 3 plays a critical role in cell-survival and… (More)
Is this relevant?
Review
2014
Review
2014
Molecular pathways: HER3 targeted therapy.
The HER family of receptor tyrosine kinases, including EGF receptor (EGFR), HER2, HER3, and HER4, transduce growth-promoting… (More)
Is this relevant?
2014
2014
Molecular Pathways Molecular Pathways: HER3 Targeted Therapy
The HER family of receptor tyrosine kinases, including EGF receptor (EGFR), HER2, HER3, and HER4, transduce growth-promoting… (More)
  • figure 1
  • figure 2
Is this relevant?
2013
2013
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
HER2/HER3 dimerization resulting from overexpression of HER2 or neuregulin (NRG1) in cancer leads to HER3-mediated oncogenic… (More)
  • table 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110a Inhibitor Potently Blocks PI3K Signaling and Growth of HER2þ Breast Cancers
We examined the effects of LJM716, an HER3 (ERBB3) neutralizing antibody that inhibits ligand-induced and ligand-independent HER3… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 4
Is this relevant?
2013
2013
Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
We examined the effects of LJM716, an HER3 (ERBB3) neutralizing antibody that inhibits ligand-induced and ligand-independent HER3… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 4
Is this relevant?